Targeted delivery of temozolomide by nanocarriers based on folic acid-hollow TiO -nanospheres for the treatment of glioblastoma.

Minerva Uribe-Robles, Emma Ortiz-Islas, Ekaterina Rodriguez-Perez, Francisca Fernández Valverde, Taehoon Lim, Alfredo A Martinez-Morales

Journal: Biomaterials advances 2023;151():213442

PMID: 37207587

Full Text on Elsevier Science View on PubMed

Abstract

Glioblastoma multiforme (GBM) is a highly malignant brain tumor. Its standard treatment includes a combination of surgery, radiation, and chemotherapy. The last involves the oral delivery of free drug molecules to GBM such as Temozolomide (TMZ). However, this treatment has limited effectiveness owing to the drugs premature degradation, lack of cell selectivity, and poor control of pharmacokinetics. In this work, the development of a nanocarrier based on hollow titanium dioxide (HT) nanospheres functionalized with folic acid (HT-FA) for the targeted delivery of temozolomide (HT-TMZ-FA) is reported. This approach has the potential benefits of prolonging TMZ degradation, targeting GBM cells, and increasing TMZ circulation time. The HT surface properties were studied, and the nanocarrier surface was functionalized with folic acid as a potential targeting agent against GBM. The loading capacity, protection from degradation, and drug retention time were investigated. Cell viability was performed to assess the cytotoxicity of HT against LN18, U87, U251, and M059K GBM cell lines. The cell internalization of HT configurations (HT, HT-FA, HT-TMZ-FA) was evaluated to study targeting capabilities against GBM cancer. Results show that HT nanocarriers have a high loading capacity, retain and protect TMZ for at least 48 h. Folic acid-functionalized HT nanocarriers successfully delivered and internalized TMZ to glioblastoma cancer cells with high cytotoxicity through autophagic and apoptotic cellular mechanisms. Thus, HT-FA nanocarriers could be a promising targeted delivery platform for chemotherapeutic drugs for the treatment of GBM cancer.

Address: Materials Science and Engineering Program, University of California, Riverside, CA 92521, USA; College of Engineering Center for Environmental Research and Technology, University of California, Riverside, CA 92507, USA.; Laboratory of Molecular Neuropharmacology and Nanotechnology, National Institute of Neurology and Neurosurgery, Insurgentes sur 3877, Tlalpan, México City 14269, Mexico. Electronic address: [email protected].; Laboratory of Molecular Neuropharmacology and Nanotechnology, National Institute of Neurology and Neurosurgery, Insurgentes sur 3877, Tlalpan, México City 14269, Mexico.; Experimental Neuropathology Laboratory, National Institute of Neurology and Neurosurgery, Insurgentes sur 3877, Tlalpan, México City 14269, Mexico.; Materials Science and Engineering Program, University of California, Riverside, CA 92521, USA; College of Engineering Center for Environmental Research and Technology, University of California, Riverside, CA 92507, USA. Electronic address: [email protected].

DOI: 10.1016/j.bioadv.2023.213442

Link outs

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S2772...

MeSH Terms: Humans, Temozolomide, Glioblastoma, Nanospheres, Folic Acid, Cell Line, Tumor